THROMBOPHILIA, THROMBOSIS AND ANTITHROMBOTIC THERAPY IN CANCER PATIENTS

Abstract

The clinical lection describes current views about pathogenesis of thrombotic complications in cancer patients. At the same time the risk of iatrogenic thrombophilia under the conditions of radio-, chemotherapy and hormone replacement therapy is considered. Issues concerning scientific explanation of antithrombotic prophylaxis with LMWH are given.

Keywords

• pathogenesis of thrombotic complications
• cancer patients
• thrombosis prevention
• hemostasis abnormalities
• low molecular weight heparin
• unfractionated heparin